Direct testing for kpc-mediated carbapenem resistance from blood samples using a t2 magnetic resonance based assay

Giulia De Angelis, Riccardo Paggi, Raffaela Paggi, Thomas J. Lowery, Jessica L. Snyder, Giulia Menchinelli, Maurizio Sanguinetti, Brunella Posteraro, Antonella Mencacci

Research output: Contribution to journalArticle

Abstract

Molecular-based carbapenem resistance testing in Gram-negative bacterial bloodstream infections (BSIs) is currently limited because of the reliance on positive blood culture (BC) samples. The T2Resistance™ panel may now allow the detection of carbapenemase-and other β-lactamase encoding genes directly from blood samples. We detected carbapenem resistance genes in 11 (84.6%) of 13 samples from patients with BC-documented BSIs (10 caused by KPC-producing Klebsiella pneumoniae and 1 caused by VIM/CMY-producing Citrobacter freundii). Two samples that tested negative for carbapenem resistance genes were from patients with BC-documented BSIs caused by KPC-producing K. pneumoniae who were receiving effective antibiotic therapy. In conclusion, our findings suggest that the T2Resistance™ panel can be a reliable tool for diagnosing carbapenem-resistant Gram-negative bacterial BSIs.
Original languageEnglish
Pages (from-to)950-N/A
JournalAntibiotics
Volume10
DOIs
Publication statusPublished - 2021

Keywords

  • Antimicrobial resistance
  • Blood sample
  • Bloodstream infection
  • Direct detection
  • KPC carbapenemase
  • Magnetic resonance
  • T2Resistance panel

Fingerprint

Dive into the research topics of 'Direct testing for kpc-mediated carbapenem resistance from blood samples using a t2 magnetic resonance based assay'. Together they form a unique fingerprint.

Cite this